Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection Updated version, April 2016 | National Resource for Infection Control (NRIC)

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection Updated version, April 2016

Best practice, Care guideline
Abstract: 
The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority. These medicines, called direct-acting antivirals (DAAs), are transforming the treatment of HCV, enabling regimens that can be administered orally, are of shorter duration (as short as eight weeks), result in cure rates higher than 90%, and are associated with fewer serious adverse events than the previous interferon- containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines
Authors: 
World Health Organization (WHO)
Category: 
Control
Management
Prevention